Continuing Medical Education: Oncology and Pulmonology CME 2012: Perspectives in Lung Cancer: 13th European Congress: Imedex: Amsterdam, The Netherlands: March 9-10, 2012
Perspectives in Lung Cancer: 13th European Congress
CME Sponsor:
Imedex
Location:
Amsterdam RAI Convention Center
Amsterdam, The Netherlands
Course Directors:
Pieter E. Postmus, MD, PhD
Chair
Giorgio V. Scagliotti, MD, PhD
Chair
Number of Credits:
TBA
Registration:
Link
Detailed Description:
This educational activity is intended for medical and radiation oncologists, thoracic surgeons, pulmonologists, physicians in- training and other healthcare professionals in active clinical practice interested and/or involved in the management of patients with thoracic cancer. As the field of lung cancer research and treatment is everevolving, this comprehensive focus on the multimodal and state-of-the-art management of lung cancer in Europe is sure to be a rewarding educational experience from all lung cancer-related disciplines.
Details are currently being finalized on this event, and information will be posted as soon as possible. In the meantime, mark your calendars for March 9-10, 2012 and check back regularly for updated information.
Imedex
Location:
Amsterdam RAI Convention Center
Amsterdam, The Netherlands
Course Directors:
Pieter E. Postmus, MD, PhD
Chair
Giorgio V. Scagliotti, MD, PhD
Chair
Number of Credits:
TBA
Registration:
Early: $399
If payment received by 12 January 2012
Discounted: $499
If payment received by 1 March 2012
Regular: $599
If payment received after 1 March 2012
Nurses/Residents/Students* $149
*Proof of eligibility must accompany registration; cannot be combined with any other discounts.
For easy registration or any questions, please call toll free at 1-855-276-6855.
Link
Detailed Description:
This educational activity is intended for medical and radiation oncologists, thoracic surgeons, pulmonologists, physicians in- training and other healthcare professionals in active clinical practice interested and/or involved in the management of patients with thoracic cancer. As the field of lung cancer research and treatment is everevolving, this comprehensive focus on the multimodal and state-of-the-art management of lung cancer in Europe is sure to be a rewarding educational experience from all lung cancer-related disciplines.
Objectives
After successful completion of this course, participants should be able to:
- Evaluate the use of biomarkers for the molecular diagnosis of lung cancer and to predict the efficacy of targeted agents
- Describe and evaluate emerging early detection strategies for lung cancer in Europe
- Compare and contrast invasive versus non-invasive (MRI, CT, PET) procedures in the staging of lung cancer
- Discuss issues and controversies related to the evolving treatment paradigms in front line metastatic NSCLC
- Examine the role of radiotherapy and emerging radiotherapeutic techniques in lung cancer
- Summarize the clinical use of systemic therapies in early-stage lung cancer treatment and incorporate them into practice
- Describe new agents in the treatment of thoracic malignancies, and increase the frequency with which biologically distinct patients are enrolled into appropriate clinical trials
- Analyze the current therapeutic management of mesothelioma and unique populations of patients with thoracic malignancies throughout Europ
Details are currently being finalized on this event, and information will be posted as soon as possible. In the meantime, mark your calendars for March 9-10, 2012 and check back regularly for updated information.
where
Comments
